logo
Plus   Neg
Share
Email

Reports: Samsung Plans To Double Smartphone Sales This Year

South Korea's Samsung Electronics Co. Ltd. (SSNLF.PK, SSNNF.PK) plans to sell 380 million mobile handsets and double its sales of smartphones this year, reports said quoting J.K. Shin, president of Samsung's mobile communications division.

Shin was speaking to reporters before the Mobile World Congress trade show in Barcelona, which will be on from February 27 to March 1. The company is expected to introduce several new products at the show, including the new 10.1-inch Galaxy Note and the Galaxy Beam, a projector smartphone.

Samsung said last month that its fourth-quarter profit was boosted by strong sales of its Galaxy smartphones, more than offsetting weakness in flat panels and computer chips. The company's smartphone business also reportedly surpassed major rivals, including Apple Inc. (AAPL), in shipments.

The company sold about 97 million units of smartphones and 327.4 million handsets last year.

The stock is currently down about 0.6 percent on the Kospi at 1,173,000 Korean won.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT